# Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia

> **NCT02735291** · NA · UNKNOWN · sponsor: **Sinobioway Cell Therapy Co., Ltd.** · enrollment: 72 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** CD19-targeted CAR-T cells

## Key facts

- **NCT ID:** NCT02735291
- **Lead sponsor:** Sinobioway Cell Therapy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11
- **Primary completion:** 2019-12
- **Final completion:** 2025-12
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2020-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02735291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02735291, "Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02735291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*